Does PERISCOPE provide a new perspective on diabetic treatment?

PERISCOPE is a double blind randomised multi center study published in recent JAMA.

PERISCOPE results come in the wake of PROACTIVE, which showed a nonsignificant 10% reduction in its primary end point of all macrovascular events and a significant 16% reduction in its secondary end point of death, MI, and stroke with pioglitazone.

What this study now tells us is: we must do a comparator effectiveness trial looking at different diabetes treatment strategies. We can't just focus on pricking the finger, getting the blood sugar down, and saying, that's the goal of therapy. The goal in therapy is to prevent complications of diabetes, and the most feared, most serious complication is heart disease, which will kill 75% of diabetics